People

Leadership

Smiling woman with glasses against grey background


Tippi C. MacKenzie, MD
CGS Director
UCSF

Role

Dr. Tippi MacKenzie is a pediatric and fetal surgeon who is focused on developing better ways to diagnose and treat genetic diseases before birth.

smiling woman with long red hair in outdoor setting


Emma Canepa, MS, CCRP
Clinical Research Manager
UCSF

Role

Emma Canepa oversees, plans, and directs the CGS and other clinical research projects, and evaluates and analyzes clinical data.

Smiling woman in print top with blue sky behind


Billie Lianoglou, LCGC
Genetic Counselor
UCSF

Role

Billie Lianoglou works closely with doctors who specialize in high-risk pregnancies to educate families on potential genetic risks for fetal abnormalities or complications.

A young woman in glasses, lab coat, in science setting smiles


Kun Jia, PhD
Postdoctoral Scholar
UCSF

Role

Kun Jia, a scholar in the Cromer Lab, develops and optimizes precise base editing technologies, multiplex genome editing strategies, and sensitive off-target detection methods.

smiling woman with long brown hair


Hind Al Saif, MD
Medical Geneticist
UCSF

Role

Hind Al Saif focuses on translating advances in gene editing and other precision genetic therapies into clinical care through research on inherited genetic disorders.

Smiling man in a blue collared shirt, blazer and tie against grey background


Christopher Dvorak, MD
Pediatric Hematologist-Oncologist
UCSF

Role

Christopher Dvorak is a specialist in stem cell transplantation for children with immunodeficiencies, blood disorders, and cancer.

Scientific Review Board (CGS Core)

The Scientific Review Board (SRB) evaluates whether a proposed gene therapy has sufficient scientific justification and development maturity to support clinical investigation.

Is the proposed therapeutic sufficiently supported by scientific and manufacturing evidence to justify advancement toward clinical use?

Enrollment Advisory Board

The Enrollment Advisory Board evaluates whether an individual patient is an appropriate candidate for treatment with a proposed bespoke gene therapy.

Is this individual an appropriate candidate to receive the proposed gene therapy?